Derazantinib

DB14889InvestigationalSmall molecule

Derazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).

Mechanism: Pharmacologically active on Fibroblast growth factor receptor
Curator reviewed
Formula / weight: C₂₉H₂₉FN₄O · 468.576 g/mol (avg)

Resolves to

Compound

UNIIN9B0H171MJCAS1234356-69-4ChEMBLCHEMBL4297187

Structure

InChIKeyKPJDVVCDVBFRMU-AREMUKBSSA-NSMILESCOCCNCCC1=CC(NC2=NC=C3C[C@@H](C4=CC=CC=C4F)C4=CC=CC=C4C3=N2)=CC=C1

Targets

P11362FGFR1

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Derazantinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account